Blog Archives for category Treatment

Press Release – Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

Today, Boehringer Ingelheim sent out a press release, announcing that, “…┬áthe European Commission (EC) and U.S. Food and Drug Administration… Continue reading »

Inventiva receives positive opinion on orphan drug designation in the European Union for IVA337 – a treatment for Systemic Sclerosis (SSc)

With few approved drugs available in SSc, this approach could significantly improve the treatment options in the future. Dijon, France,… Continue reading »

New therapies – AIMSPRO

The Food and Drug Administration has at the end of February 2014 granted Orphan Drug designation to the therapy AIMSPRO,… Continue reading »

New treatment being investigated for Systemic Sclerosis

Systemic sclerosis (SSc) is a rapidly progressing systemic form of scleroderma for which there are currently no approved treatments SSc… Continue reading »